Erin Larkins

1.9k total citations
28 papers, 937 citations indexed

About

Erin Larkins is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Erin Larkins has authored 28 papers receiving a total of 937 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Pulmonary and Respiratory Medicine, 21 papers in Oncology and 7 papers in Cancer Research. Recurrent topics in Erin Larkins's work include Lung Cancer Treatments and Mutations (17 papers), Cancer Immunotherapy and Biomarkers (15 papers) and Cancer Genomics and Diagnostics (7 papers). Erin Larkins is often cited by papers focused on Lung Cancer Treatments and Mutations (17 papers), Cancer Immunotherapy and Biomarkers (15 papers) and Cancer Genomics and Diagnostics (7 papers). Erin Larkins collaborates with scholars based in United States, Hong Kong and China. Erin Larkins's co-authors include Richard Pazdur, Gideon M. Blumenthal, Patricia Keegan, Kirsten B. Goldberg, Pallavi S. Mishra‐Kalyani, Amy E. McKee, Luckson Mathieu, Harpreet Singh, Julia A. Beaver and Rajeshwari Sridhara and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and Clinical Cancer Research.

In The Last Decade

Erin Larkins

26 papers receiving 926 citations

Peers

Countries citing papers authored by Erin Larkins

Since Specialization

Citations

This map shows the geographic impact of Erin Larkins's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erin Larkins with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erin Larkins more than expected).

Fields of papers citing papers by Erin Larkins

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erin Larkins. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erin Larkins. The network helps show where Erin Larkins may publish in the future.

Co-authorship network of co-authors of Erin Larkins

This figure shows the co-authorship network connecting the top 25 collaborators of Erin Larkins. A scholar is included among the top collaborators of Erin Larkins based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erin Larkins. Erin Larkins is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	An FDA analysis of the association of tumor growth rate, overall survival, and progression-free survival in patients with metastatic non-small cell lung cancer 2026 ·The Oncologist ·(unknown), Jiaxin Fan, Joyce Cheng, Yutao Gong, (unknown), Erin Larkins	0
2	FDA analysis of immune checkpoint inhibitors in combination with vascular endothelial growth factor tyrosine kinase inhibitors in the second-line treatment of patients with advanced non-small cell lung cancer. 2024 ·Journal of Clinical Oncology ·(unknown), Gautam U. Mehta, Paz J. Vellanki, Erin Larkins, Paul G. Kluetz, Harpreet Singh	0
3	Correlations of response rate and progression-free survival with overall survival in immunotherapy trials for metastatic non-small-cell lung cancer: an FDA pooled analysis 2024 ·The Lancet Oncology ·Bernardo H. L. Goulart, Sirisha L. Mushti, (unknown), Erin Larkins, Pallavi S. Mishra‐Kalyani, Richard Pazdur, Paul G. Kluetz, Harpreet Singh	11
4	Most Common Symptomatic Adverse Reactions of Cancer Treatments From US Drug Labels (2015-2021) to Inform Selection of Patient-Reported Outcomes 2024 ·Value in Health ·(unknown), (unknown), (unknown), Bindu Kanapuru, Laleh Amiri‐Kordestani, Erin Larkins, Paul G. Kluetz, Vishal Bhatnagar	1
5	Impact of Increasing PD-L1 Levels on Outcomes to PD-1/PD-L1 Inhibition in Patients With NSCLC: A Pooled Analysis of 11 Prospective Clinical Trials 2024 ·The Oncologist ·Jonathon Vallejo, Harpreet Singh, Erin Larkins, Nicole Drezner, Biagio Ricciuti, Pallavi S. Mishra‐Kalyani, Shenghui Tang, Julia A. Beaver, Mark M. Awad	5
6	US Food and Drug Administration Approval Summary: Nivolumab Plus Platinum-Doublet Chemotherapy for the Neoadjuvant Treatment of Patients With Resectable Non–Small-Cell Lung Cancer 2023 ·Journal of Clinical Oncology ·Oladimeji Akinboro, Nicole Drezner, Anup Amatya, (unknown), (unknown), Miao Zhao, Youwei Bi, Kwadwo Ameyaw Korsah, Bronwyn D. Mixter, Shenghui Tang, Erin Larkins, Richard Pazdur, Julia A. Beaver, Harpreet Singh	23
7	FDA Approval Summary: Amivantamab for the Treatment of Patients with Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations 2023 ·Clinical Cancer Research ·(unknown), Erin Larkins, (unknown), Pallavi S. Mishra‐Kalyani, Stephanie Aungst, Emily Wearne, Sriram Subramaniam, (unknown), (unknown), Jielin Sun, Rosane Charlab, (unknown), (unknown), Rama Kamesh Bikkavilli, Soma Ghosh, Reena Philip, Julia A. Beaver, Harpreet Singh	33
8	Evaluating Pneumonitis Incidence in Patients with Non–small Cell Lung Cancer Treated with Immunotherapy and/or Chemotherapy Using Real-world and Clinical Trial Data 2023 ·Cancer Research Communications ·Qi Liu, Chenan Zhang, (unknown), (unknown), Shiew‐Mei Huang, Erin Larkins, (unknown), Donna R. Rivera, Paul G. Kluetz, Shenggang Wang, Hao Zhu, James L. Weese, (unknown), (unknown), (unknown), (unknown), (unknown)	2
9	FDA Approval Summary: Atezolizumab as Adjuvant Treatment following Surgical Resection and Platinum-Based Chemotherapy for Stage II to IIIA NSCLC 2023 ·Clinical Cancer Research ·Luckson Mathieu, Erin Larkins, A. K. Sinha, Pallavi S. Mishra‐Kalyani, (unknown), Shyam Kalavar, Soma Ghosh, Kirsten B. Goldberg, Richard Pazdur, Julia A. Beaver, Harpreet Singh	27
10	The Association Between Baseline Hepatic or Renal Function and Clinical Outcomes for Patients With Non‐Small Cell Lung Cancer Treated With a PD‐1/PD‐L1 Blocking Antibody Using Real‐World and Trial Data 2023 ·Clinical Pharmacology & Therapeutics ·Qi Liu, (unknown), Yuan Xu, Aracelis Z. Torres, Rebecca A. Miksad, Chao Liu, (unknown), Yaning Wang, Hao Zhu, Brian Booth, Shiew‐Mei Huang, Jizu Zhi, Rajeshwari Sridhara, Gideon M. Blumenthal, Erin Larkins, Pallavi S. Mishra‐Kalyani, Donna R. Rivera, Paul G. Kluetz, Elad Sharon	3
11	Outcomes of anti–PD-(L)1 therapy with or without chemotherapy (chemo) for first-line (1L) treatment of advanced non–small cell lung cancer (NSCLC) with PD-L1 score ≥ 50%: FDA pooled analysis. 2022 ·Journal of Clinical Oncology ·Oladimeji Akinboro, Jonathon Vallejo, Erica C. Nakajima, Yi Ren, Pallavi S. Mishra‐Kalyani, Erin Larkins, Paz J. Vellanki, Nicole Drezner, Luckson Mathieu, Martha Donoghue, Shenghui Tang, Richard Pazdur, Julia A. Beaver, Harpreet Singh	37
12	FDA Approval Summary: Atezolizumab and Durvalumab in Combination with Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung Cancer 2021 ·The Oncologist ·Luckson Mathieu, Sujay Shah, Lee H. Pai-Scherf, Erin Larkins, Jonathon Vallejo, Xiaoxue Li, Lisa Rodríguez, Pallavi S. Mishra‐Kalyani, Kirsten B. Goldberg, Paul G. Kluetz, Marc R. Theoret, Julia A. Beaver, Richard Pazdur, Harpreet Singh	102
13	US Food and Drug Administration regulatory updates in neuro-oncology 2021 ·Journal of Neuro-Oncology ·Gautam U. Mehta, Amy Barone, Diana Bradford, Erin Larkins, (unknown), Lee H. Pai-Scherf, (unknown), Mirat Shah, Suparna Wedam, Laleh Amiri‐Kordestani, Marc R. Theoret, Richard Pazdur, Julia A. Beaver, Harpreet Singh	8
14	FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring BRAF V600E Mutations 2018 ·The Oncologist ·Lauretta Odogwu, Luckson Mathieu, Gideon M. Blumenthal, Erin Larkins, Kirsten B. Goldberg, (unknown), Karen E. Bijwaard, Eunice Lee, Reena Philip, Xiaoping Jiang, Lisa Rodríguez, Amy E. McKee, Patricia Keegan, Richard Pazdur	166
15	FDA analyses of survival in older adults with metastatic non–small cell lung cancer in controlled trials of PD-1/PD-L1 blocking antibodies 2018 ·Seminars in Oncology ·Shanthi Marur, Harpreet Singh, Pallavi S. Mishra‐Kalyani, Erin Larkins, Patricia Keegan, Rajeshwari Sridhara, Gideon M. Blumenthal, Richard Pazdur	66
16	FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation 2017 ·The Oncologist ·Lauretta Odogwu, Luckson Mathieu, Kirsten B. Goldberg, Gideon M. Blumenthal, Erin Larkins, Mallorie H. Fiero, Lisa Rodríguez, Karen E. Bijwaard, Eunice Y. Lee, Reena Philip, (unknown), Martha Donoghue, Patricia Keegan, Amy S. McKee, Richard Pazdur	49
17	FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy 2017 ·The Oncologist ·Erin Larkins, Gideon M. Blumenthal, Weishi Yuan, Kun He, Rajeshwari Sridhara, Sriram Subramaniam, Hong Zhao, Chao Liu, Jingyu Yu, Kirsten B. Goldberg, Amy E. McKee, Patricia Keegan, Richard Pazdur	172
18	Clinician Perspectives on Current Issues in Lung Cancer Drug Development 2016 ·Journal of Thoracic Oncology ·Saiama N. Waqar, Philip Bonomi, Ramaswamy Govindan, Fred R. Hirsch, Gregory J. Riely, Vassiliki A. Papadimitrakopoulou, Dickran Kazandjian, Sean Khozin, Erin Larkins, (unknown), Shakun Malik, Leora Horn, Andrea Ferris, Alice T. Shaw, Pasi A. Jänne, Tony Mok, Roy S. Herbst, Patricia Keegan, Richard Pazdur, Gideon M. Blumenthal	8
19	U.S. Food and Drug Administration Approval Summary: Ramucirumab for the Treatment of Metastatic Non-Small Cell Lung Cancer Following Disease Progression On or After Platinum-Based Chemotherapy 2015 ·The Oncologist ·Erin Larkins, Barbara Scepura, Gideon M. Blumenthal, Erik Bloomquist, Shenghui Tang, (unknown), Paul G. Kluetz, Patricia Keegan, Richard Pazdur	31
20	A Phase II Study of Sorafenib Combined With Cetuximab in EGFR-Expressing, KRAS-Mutated Metastatic Colorectal Cancer 2015 ·Clinical Colorectal Cancer ·T. Khanh, Liang Cao, Zhigang Kang, Barış Türkbey, Maria Liza Lindenberg, Erin Larkins, Beata Holkova, Seth M. Steinberg, Mark Raffeld, Cody J. Peer, William D. Figg, Michelle Eugeni, Paula Jacobs, Peter L. Choyke, James R. Wright, James H. Doroshow, Shivaani Kummar	22

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact